

1 **Co-development of an evidence-based personalised smoking cessation intervention for use in a**
2 **lung cancer screening context**

3
4
5 Harriet D. Quinn-Scoggins¹, Rachael L. Murray ², Samantha L. Quaife³, Pamela Smith¹, Kate E. Brain¹,
6 Matthew E.J. Callister⁴, David R. Baldwin⁵, John Britton², Philip A.J. Crosbie⁶, Rebecca Thorley² and
7 Grace M. McCutchan¹

8 **Corresponding author:** Dr Harriet D. Quinn-Scoggins

9 Address: Division of Population Medicine, Cardiff University, 8th Floor Neuadd Meirionnydd, Heath
10 Park, Cardiff, CF14 4YS
11 Email: Quinn-ScogginsHD@Cardiff.ac.uk
12 Tel: +44(0)29 20687945
13
14

15 **Author affiliations:**

16 ¹Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK

17 ²Academic Unit of Lifespan and Population Health, School of Medicine, University of Nottingham,
18 Nottingham, UK

19 ³Wolfson Institute of Population Health, Queen Mary University of London, London, UK

20 ⁴Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, St James's University
21 Hospital, Leeds, UK

22 ⁵Department of Respiratory Medicine, Nottingham University Hospital, Nottingham, UK

23 ⁶Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health,
24 University of Manchester, Manchester, UK

25 **Word count: 3,708**

26 **Key words:** Lung Cancer, lung cancer screening, emphysema, smoking cessation, intervention,
27 Imaging/CT MRI; patient and public involvement; co-development

28

29

30

31

32

1 **ABSTRACT (349/350 words)**

2 **Background:** Optimising smoking cessation services within a low radiation-dose computed
3 tomography (LDCT) lung cancer screening programme has the potential to improve cost-
4 effectiveness and overall efficacy of the programme. However, evidence on the optimal design and
5 integration of cessation services is limited. We co-developed a personalised cessation and relapse
6 prevention intervention incorporating clinical and medical imaging collected during lung cancer
7 screening. The intervention is designed to initiate and support quit attempts among smokers
8 attending screening as part of the Yorkshire Enhanced Stop Smoking study (YESS: ISRCTN63825779).
9 Patients and public were involved (PPI) in the development of an acceptable intervention designed
10 to meet the needs of the target population.

11 **Methods:** An iterative co-development approach was used. Eight members of the public with a
12 history of smoking completed an online survey to inform the visual presentation of risk information
13 in subsequent focus groups for acceptability testing. Three focus groups (n=13) were conducted in
14 deprived areas of Yorkshire and South Wales with members of the public who were current smokers
15 or recent quitters (within the last year). Exemplar images of the heart and lungs acquired by LDCT,
16 absolute and relative lung cancer risk, and lung age were shown. Data were analysed thematically,
17 and discussed in stakeholder workshops. Draft versions of the intervention were developed,
18 underpinned by the Extended Parallel Processing Model to increase self-efficacy and response-
19 efficacy. The intervention was further refined in a second stakeholder workshop with a PPI panel.

20 **Results:** Individual LDCT scan images of the lungs and heart, in conjunction with artistic impressions
21 to facilitate interpretation, were considered by public participants to be most impactful in prompting
22 cessation. Public participants thought it important to have a trained practitioner guiding them
23 through the intervention and emphasising the short-term benefits of quitting. Presentation of
24 absolute and relative risk of lung cancer and lung age were considered highly demotivating due to
25 reinforcement of fatalistic beliefs.

1 **Conclusion:** An acceptable personalised intervention booklet utilising LDCT scan images has been
2 developed for delivery by a trained smoking cessation practitioner. Our findings highlight the benefit
3 of co-development during intervention development and the need for further evaluation of
4 effectiveness.

5 **PLAIN ENGLISH SUMMARY (248/ 250 words)**

6 Supporting patients to stop smoking when they attend lung cancer screening will improve the overall
7 benefit and value for money of the service. This study developed a booklet containing pictures of a
8 person's own lungs and heart taken during a lung cancer screening scan. The booklet shows areas of
9 damage to the heart and lungs caused by smoking, delivered alongside positive messages to build
10 confidence to stop smoking and let patients know about the benefits of stopping smoking.

11 To develop the booklet, we worked with members of public who currently or used to smoke. Eight
12 members of public completed a survey asking about the best ways to present information about risk.
13 Thirteen members of the public took part in focus groups to co-develop the booklet. One workshop
14 with academic and healthcare professionals and one workshop with a public involvement panel
15 were held to develop and finalise the booklet.

16 Members of the public said they wanted information about the short-term benefits of quitting
17 smoking, and that coloured drawings next to the scan picture would help them to understand what
18 the scan picture meant. Having someone specially trained to guide them through the booklet was
19 considered important. Being told about their risk for lung cancer in the future was off-putting and
20 might discourage a quit attempt.

21 We have co-developed a booklet to support people to quit smoking when they go for lung cancer
22 screening. The booklet is currently being tested to see whether it can support people to quit
23 smoking.

1

2 **BACKGROUND**

3 Lung cancer has the highest mortality of all cancers in the UK.[1] More than 85% of lung cancer cases
4 are caused by tobacco smoking,[2] and smoking cessation at any age significantly reduces lung
5 cancer risk.[3,4] Lung cancer screening with annual low-dose computed tomography (LDCT) has
6 been shown to reduce lung cancer mortality in high-risk groups by 20%, and is widely available in
7 some high-income countries such as the United States[5]. Results from the Dutch-Belgian NELSON
8 study report substantially lower lung cancer mortality when compared to no screening, even when
9 screening intervals are increased over time.[6] In the UK it is available as part of the Targeted Lung
10 Health Check programme and is currently awaiting a final decision on approval from the UK National
11 Screening Committee.

12 Empirical evidence suggests that lung cancer screening can act as a 'teachable moment' to
13 encourage smoking cessation.[7] Integrating screening and smoking cessation services can improve
14 the overall success and cost-effectiveness of lung cancer screening.[8-13] The UK Lung Screening
15 Trial reported net cessation rates of 15% at two-year follow-up, compared to 4% in the general
16 population.[14] Where smoking cessation interventions have previously been included in lung
17 cancer screening, they have typically been brief and low intensity involving signposting to external
18 services (e.g. 15). Low intensity interventions are likely to be inadequate for the population of long-
19 term (and often life-long) smokers eligible for lung cancer screening who typically have higher
20 dependence on nicotine,[16] less success in quitting,[17] and are over-represented in
21 socioeconomically deprived groups where cessation is most challenging.[18] Novel, higher intensity
22 smoking cessation interventions may be needed to support and sustain quit attempts in individuals
23 at high risk of developing lung cancer; such interventions delivered at the point of screening have
24 the potential to increase cessation rates in socioeconomically deprived populations [19-21].

1 Interventions should be developed in consultation with eligible members of the public to ensure the
2 intervention developed meets the needs of the target population [22].

3 Research outside of the lung screening setting suggests that interventions using visual or imaging
4 techniques can effectively promote smoking cessation.[23,24] Visual feedback has the potential to
5 strengthen risk communication as imaging results can reveal visible evidence of bodily harm
6 attributable to smoking that is immediately comprehensible to the patient.[24,25] Using clinical
7 information and imaging obtained from LDCT scans during a lung cancer screening appointment
8 could therefore prove an effective motivational tool, providing a higher intensity, personalised
9 intervention better suited to the high-risk target population, especially when developed in
10 collaboration with potential service users. The current study was underpinned by the Extended
11 Parallel Process Model (EPPM; [26]) as a conceptual framework for understanding individual
12 variation in the behavioural response to receiving personal risk information. The EPPM proposes
13 that when a high level of threat is perceived, an individual will only engage in protective behaviours
14 ('danger control') if they are confident in their ability to enact the behaviour (self-efficacy) and they
15 believe that the behaviour will be effective in reducing their risk (response efficacy). In a scenario
16 where these efficacy beliefs are low, an individual will respond defensively to high threat
17 information and engage in avoidant behaviours that reduce their negative emotional arousal ('fear
18 control'). In the context of lung cancer screening, personalised risk interventions should therefore
19 be designed to enhance perceptions of self-efficacy and response-efficacy if they are to effectively
20 motivate smoking cessation efforts in response to the threat associated with visualising personal risk
21 of heart and lung disease.

22 The current study is the first to report the co-development of a bespoke smoking cessation and
23 relapse prevention intervention for the Yorkshire Enhanced Stop Smoking Study (YESS;
24 ISRCTN63825779 [27]), underpinned by the EPPM [26] and embedded within the Yorkshire Lung
25 Screening Trial (YLST; ISRCTN42704678 [28]). YLST aims to describe participation among people at

1 highest risk of lung cancer and clarify the optimal strategy for defining a high-risk population for
2 screening in the. YESS is currently testing the effectiveness of the intervention reported and how to
3 best integrate smoking cessation in a lung cancer screening setting.

4 Following the principles of co-production in healthcare and the MRC complex intervention
5 development guidance,[22,29] key stakeholders were involved (members of the public, health
6 professionals and academic partners) to co-develop the materials for the YESS intervention - a
7 personalised risk information booklet (including images of the participant's scan from their screening
8 appointment alongside personalised risk text and practitioner scripts; both designed to enhance self-
9 efficacy and response-efficacy) and personalised on-going support provided by a trained smoking
10 cessation practitioner. Members of the public were involved throughout intervention development
11 to ensure that the booklet was acceptable to the target population to potentially increase overall
12 impact and effectiveness of the intervention.

13 **METHODS**

14 Intervention materials were developed iteratively. Acceptability and format preferences regarding
15 personalised risk intervention components (absolute and relative lung cancer risk, lung scan images
16 showing emphysema, heart scan images showing coronary heart calcification, and lung age) were
17 collected sequentially through a series of focus groups. Prior to this, the selection of images to be
18 presented in the focus groups was initially informed by the findings of an online survey involving
19 members of the public who smoke. Intervention materials were further refined through two
20 stakeholder workshops. Participants were shown hypothetical examples of risk information and
21 advised that the final intervention would include images based on their individual clinical data from
22 lung cancer screening. Examples of visual risk materials presented by intervention component are
23 provided in Figure 1. All visual risk materials, survey questions and focus group topic guides are
24 provided in Additional Files 1 and 2. Ethical approval for the study was gained from the Cardiff
25 University School of Medicine Research Ethics Committee (ref 17/51).

1 (INSERT FIGURE 1)

2 Figure 1 - Examples of Online Survey and Focus Group Materials

3 Figure 1 (legend) **A.** Bar chart showing absolute and relative lung cancer risk **B.** Pictogram showing
4 absolute lung cancer risk **C.** Pie chart showing absolute lung cancer risk **D.** Lung scan images showing
5 emphysema **E.** Heart scan images showing coronary artery calcification **F.** Lung age text

6

7 **Online Survey**

8 An online survey was conducted to inform the selection of visual presentations of lung cancer risk
9 that were subsequently presented for feedback in the focus groups. The online survey (Additional
10 File 1) was distributed via Survey Monkey to an established patient and public involvement group for
11 tobacco related research in the East Midlands, convened by the UK Centre for Tobacco and Alcohol
12 Studies. Survey participants were asked to select their preferred visual representation of absolute
13 risk and relative risk for lung cancer (pie chart, bar chart or pictogram), framing (gain, loss or partial
14 framing), time frame to present absolute lung cancer risk reduction (2 years, 5 years, 7 years or 10
15 years), and pictogram format (number and colouring of icons). A free text box and researcher
16 contact information were provided for gathering additional comments.

17 **Focus Groups**

18 Three focus groups (two in South Wales and one in Yorkshire) were conducted with people over age
19 55 years who currently smoked or had quit within the past year, recruited from highly deprived
20 areas (assessed by multiple deprivation score) through pre-existing community contacts and
21 snowball sampling.[30] Individual level deprivation (educational attainment) was assessed during
22 data collection. Preferred visual presentations of risk information from the online survey informed
23 topic guide development (Additional File 2). Members of the public were asked to provide feedback
24 on format preferences regarding: (1) personalised scan images of lungs with emphysema presented
25 alongside artist impressions of healthy areas of the lung, and as axial/dorsal views; (2) personalised
26 scan images of the heart showing coronary artery calcification presented alongside a healthy heart,

1 artist impressions of the heart, and a 3D representative heart with coloured sections to highlight
2 calcification; (3) absolute and relative risk for lung cancer shown as bar charts or pictograms, and (4)
3 lung age shown as a textual description. Focus groups were audio-recorded and transcribed
4 verbatim. Thematic analysis [31] was conducted using NVivo 11 Qualitative Data Analysis Software.

5 **Stakeholder Workshops**

6 The final intervention was developed and refined in accordance with findings from the focus groups,
7 existing literature and in two workshop-style meetings with stakeholders. The first stakeholder
8 workshop included representation from health psychologists, clinicians, specialist research nurses,
9 specialists in health policy, and researchers with extensive knowledge and experience working in
10 cancer screening and smoking cessation. Each of the intervention components were presented to
11 stakeholders in turn, showing an exemplar of how the information could be presented visually,
12 alongside existing evidence for the component and findings from the focus groups with members of
13 the public. In a facilitated discussion, stakeholders were asked to comment on the suitability of each
14 intervention component in the YESS context and acceptability/feasibility of intervention delivery.
15 The second stakeholder workshop was conducted with public and patient representatives from the
16 Nottingham Smokers Panel. A draft version of the booklet was shown to the Nottingham Smokers
17 Panel for feedback in a facilitated discussion.

18 **Patient and Public Involvement**

19 Members of the public were involved throughout intervention development, in accordance with a
20 co-development approach. A co-development approach was utilised to ensure that the intervention
21 was developed to meet the needs of the target population. The near-final version of the intervention
22 was presented to a patient and public involvement panel of people with a history of smoking. The
23 Guidance for Reporting Involvement of Patients and Public checklist guided reporting (Additional File
24 3; [32]).

1

2

3 **RESULTS**

4 **Online Survey**

5 Eight participants completed the online survey. Pictograms were favoured by five participants over
6 the bar chart (n=2) and pie chart (n=1) for visualisation of risk. There was no clear preference for the
7 time frame that would be most meaningful to present risk information (three years n=2, five years
8 n=2, seven years n=2, ten years n=2). Pictograms that presented lung cancer risk in icon arrays of
9 100 were favoured over icon arrays of 50 by six participants, with positive effects on lung cancer risk
10 with smoking cessation shown in the pictogram as green (n=5). Six participants preferred gain
11 framed statements, whereas two preferred partial framing.

12 **Focus Groups**

13 Thirteen members of the public participated across three focus groups, of whom nine currently
14 smoked and four had recently quit. Results are presented according to each intervention
15 component, with exemplary quotes.

16 ***Lung cancer absolute and relative risk***

17 Members of the public who took part in the focus groups described absolute risk information for
18 lung cancer as demotivating because it undermined the perceived benefit of quitting. The risk was
19 not considered high enough to make a difference to their smoking behaviour or prompt a quit
20 attempt. Although relative risk information was understood with ease, they focused on the
21 seemingly small absolute risk benefit of smoking cessation. How lifetime risk could be calculated was
22 queried, and most were concerned about being told their life expectancy.

23 *‘... You go through all that giving up and it’s only one in four...’* (Participant 3, Focus Group 1)

1 *'... I think looking at those odds, that wouldn't bother me, I'd carry on... It's not the fear*
2 *factor there...'* (Participant 4, Focus Group 3)

3 *'... I don't think this chart frightens you enough, it's just a chart. You have to put people here*
4 *like they are real...'* (Participant 6, Focus Group 1)

5 Fatalism was described with reference to knowing their lung cancer risk was high, and participants
6 suggested that this would evoke a fearful avoidant response instead of encouraging a quit attempt.

7 *'...Well if I tried to stop smoking and I couldn't I'd probably say c'est la vie and carry on*
8 *smoking and it wouldn't. I thought of dying as a result of smoking and the slow death that*
9 *will be endured if the lungs go and other parts of your body go and then you get cancer and*
10 *all that sort of, and whatever else...'* (Participant 3, Focus Group 2)

11 ***Lung LDCT scan images showing emphysema***

12 Lung LDCT scan images were well received. A scan image of their lungs with coloured highlighted
13 areas of damage presented alongside a library image of a healthy lung for comparison was
14 preferred. The scan image was difficult to interpret alone; participants highlighted the importance of
15 accompanying text and verbal explanation by a trained advisor.

16 *'...I think the difference between these two is the one on the right looks like a lung. The one*
17 *of the left just looks like a black and white picture. It could be a picture of any part of your*
18 *body unless you were a specialist you wouldn't know if you take the writing away...'*
19 (Participant 2, Focus Group 2)

20 *'... What we want is an internal picture, coloured picture of his lung and then mine to*
21 *compare...'* (Participant 2, Focus Group 1)

22 There was a preference for scan images of lungs to bar charts depicting risk, and some suggested
23 that scan images were a better way of communicating risk. Scan images were considered potentially

1 motivating for cessation because the images would be their own, meaning they were less able to
2 ignore the information or deny personal relevance.

3 *‘... But the lung thing is genuine, that’s what you’re breathing in. If you’re inhaling smoke and*
4 *breathing in, that is causing a problem. So a similar sort of picture but of the lung would be*
5 *definitely a lot better...’* (Participant 2, Focus Group 1)

6 *‘... Yeah because at the end of the day we’re smokers we’re a bunch of pessimists. We see*
7 *someone else’s lung, that’s not mine. If there was a picture of your own lung, you can’t deny*
8 *the fact I think...’* (Participant 1, Focus Group 30)

9 **Heart LDCT scan images showing coronary artery calcification**

10 The 3D coloured image of the heart highlighting calcification was preferred over black and white
11 scan images. Small sections showing coronary artery calcification on the 3D heart scan image were
12 easier to interpret when shown alongside an artist’s impression of a healthy and calcified artery.

13 *‘...The two together are good because the picture of the whole heart, the narrow parts are*
14 *very small and highlighted by the white. But with the expanded view of the two that gives*
15 *much more detail...’* (Participant 2, Focus Group 2)

16 **Lung age**

17 There was good comprehension that smoking increases lung age, and that increased lung age may
18 suggest early mortality. However, the impact of lung age on motivation to quit was viewed
19 negatively due to interpretation of lung damage as irreversible, evoking a fearful emotional
20 response. Most reported that lung age data would not motivate them to quit smoking.

21 *‘... It races your life too far into the future when you’re only 55. It advances you closer to*
22 *death...’* (Participant 3, Focus Group 2)

23 *‘... You can’t make it better can you... it’s irreversible...’* (Participant 3, Focus Group 1)

1 *'... It's frightening to see that but I don't think that would stop me smoking...'* (Participant 1,
2 Focus Group 2)

3 **Stakeholder Workshops**



4 Intervention refinements were made through stakeholder feedback. In the first stakeholder
5 workshop with academics and health professionals it was agreed that personalised lung and heart
6 scan images alongside explanatory artistic impressions, delivered with the support of a trained
7 advisor alongside standardised scripted verbal advice to boost self- and response-efficacy, would be
8 included in the YESS intervention. Absolute and relative lung cancer risk and lung age were removed
9 to mitigate against any potential negative effects in accordance with advice from members of the
10 public who took part in the focus groups. Following feedback from the second stakeholder workshop
11 a cost calculator to show how much money would be saved by quitting was removed because
12 patient and public involvement smoking panel representatives considered it to be naive and
13 suggested it was likely to make patients defensive and dismissive. Additionally, minor presentation
14 changes were made to the booklet in accordance with suggestions from the patient and public panel
15 representatives (e.g. images of exemplary patients were removed from the front cover).
16 Presentation adjustments were made to aid readability and comprehension, and to increase
17 personalisation.

18 **DISCUSSION**

19 To our knowledge, this study is the first to report the co-development of a bespoke visual smoking
20 cessation and relapse prevention intervention for integration in targeted lung cancer screening. Our
21 findings indicate that in high-risk adults living in socioeconomically deprived areas, personalised risk
22 interventions using LDCT scan images, alongside scripted verbal explanation that targets efficacy
23 perceptions and is delivered by trained smoking cessation practitioners (Table 1), could motivate
24 smoking cessation in a lung cancer screening context. By involving patients and members of the

- 1 public throughout intervention development and using a co-development approach, we have
- 2 developed an acceptable personalised smoking cessation intervention for use in a lung cancer
- 3 screening setting (Additional File 4).

4 **Table 1. YESS intervention components**

Intervention component	Description	Image/File
<i>Booklet</i>		Additional File 4
Heart damage	Scan image of heart obtained from LDCT screening to show calcification. Shown alongside artist impressions of the heart and arteries to aid comprehension	 Your heart This is a picture of your heart taken from your CT scan. The white areas show parts of the arteries going to your heart that have become hard or narrow. Smoking is associated with the hardening and narrowing of the heart arteries. This can lead to problems including heart attacks. This drawing shows what your heart looks like inside. The yellow parts show roughly where the arteries going to your heart have become hard or narrow. These are drawings of what healthy and narrowed arteries look like. By stopping smoking, you can reduce the chance of the arteries to your heart becoming hardened or narrowed and lower your risks of problems like heart attacks.
Lung damage	Scan image of lungs obtained from LDCT screening to show areas of damage cause my smoking (emphysema). Shown alongside another section of their lung with no damage (or a stock image if healthy section unavailable). Artist impression of the lung to aid comprehension	 Your lungs This is a picture of your lung taken from your CT scan. The parts circled in red are areas of your lung that have been damaged by smoking. This is called "emphysema". This is another picture of your lung taken from your CT scan. This is a healthy part of your lung that has not been damaged by smoking. You can keep these parts of your lung healthy if you stop smoking today. This is a drawing of what your lungs look like inside. The darker parts are the areas damaged from smoking (like the first picture). The lighter parts are healthy areas not damaged by smoking (like the middle picture). Stopping smoking will stop the healthy parts of your lungs from getting damaged.
Health benefits of smoking cessation	Generic information about the health benefits of stopping smoking	 How stopping smoking will help your health After 20 minutes - Your heart rate goes back to normal. After 8 hours - Nicotine and carbon monoxide (a poisonous gas produced when smoking) in your blood goes down by half. - Your oxygen levels go back to normal. After 2 days - You will not have any carbon monoxide left in your body. - Your lungs will be cleaner. - You will be able to taste and smell better. After 3 days - You will find it easier to breathe. - You will have more energy and walking will be easier. After 2 to 12 weeks - Your blood will flow better around your body. - This means more oxygen can get to important parts of your body. After 3 to 9 months - Your coughing and breathing will get better. - Your lungs will start to work better - they can improve by up to 50%. After 1 year - Your risk of getting heart disease will go down to about half that of a person who is still smoking. After 10 years - Your risk of getting lung cancer will go down to about half that of a person who is still smoking. After 15 years - Your risk of having a heart attack will go down to the same as someone who has never smoked. For more information get in touch with: Yorkshire Stop Smoking Study Project Manager: Rebecca Thorley 0115 423 1361 One You Leeds: 0800 169 4219 Leeds Lung Health Check Clinical Team: 0115 292 6686 For any queries related to your smoking call:
<i>Scripted advice from the smoking cessation practitioner (SCP)</i>	Booklet is delivered by the SCP, with verbal discussions facilitated using a standardised intervention script. The script is tailored to the extent of calcification	Script – Additional File 5 Smoking cessation practitioner training – Additional File 6

	and/or emphysema. The SCPs receive intervention-specific communication training by a psychologist, designed to target both personal threat and efficacy perceptions.	
--	--	--

1 Through a three-pronged intervention co-development approach (identifying the evidence base,
2 patient and public involvement, and stakeholder feedback), we have developed an intervention that
3 meets the needs of the target population. Patient and public involvement is especially important
4 when considering the sensitive and unique nature of the intervention and context of delivery in this
5 case. Not only are this high-risk population taking part in lung cancer screening, but with their likely
6 higher dependence on nicotine [17] and lower success in quitting,[18] it is essential that fatalistic
7 beliefs or blame are not reinforced by the intervention. We incorporated the views and preferences
8 of the target population to increase acceptability, relevance and engagement of the final
9 intervention.

10 Results suggest that scan images were perceived as relevant and easy to understand, and were
11 considered most likely to motivate a quit attempt because recipients would be unlikely to disregard
12 risk information based on visual imaging of their own lungs and heart. Although empirical evidence
13 regarding the effectiveness of medical images to promote health behaviour change is mixed,[33]
14 interventions using medical images have been shown to be effective when combined with
15 physician's advice [24]. A systematic review found that presenting projected health risk estimates
16 alone, even when highly personalised, did not produce strong effects on health-related behaviours
17 or sustained change.[21] Similarly, a Cochrane Review assessed the effectiveness of biomedical risk
18 assessments as an aid for smoking cessation (including biofeedback on risk exposure, smoking-
19 related disease and smoking-related harm) and found no evidence of increased cessation rates;[34].
20 This highlights the importance of providing on-going behavioural support from a trained smoking
21 cessation practitioner (Additional File 5).

1 According to the EPPM, the way in which medical images are presented and the content of the
2 accompanying advice are important in determining the behavioural impact of personalised medical
3 images. The intervention needs to not only be effective in communicating personal salience of risk,
4 but also in building self-efficacy and response-efficacy. The intervention should then sufficiently
5 increase threat perceptions in a way that motivates individuals to engage in risk-reducing behaviour
6 because they also feel able to quit and that quitting will improve their health. The YESS intervention
7 includes communication techniques and language designed to target both personal threat and
8 efficacy perceptions, interwoven throughout the intervention booklet and verbal discussions with
9 the trained smoking cessation practitioner. Verbal discussions are facilitated using a standardised
10 intervention script (Additional File 5) delivered by the smoking cessation practitioner, who is also
11 given intervention-specific communication training by a psychologist (Additional File 6). The scripts
12 and discussions are tailored to the extent of calcification and/or emphysema.

13 Members of the public found pictorial representations of absolute/relative risk and lung age harder
14 to understand and considered them demotivating for encouraging a quit attempt because they
15 reinforced fatalistic beliefs that lung damage was irreversible, undermining the perceived response
16 efficacy of smoking cessation. Previous research outcomes on the presentation of personalised risk
17 messages and projected long-term risk of health conditions in smoking cessation for current smokers
18 is varied when compared to provision of standardised general information.[35-37] Results from
19 these studies suggest that the impact of risk perceptions could be moderated by risk status placed
20 on smoking and smoking products by wider society.[35] It also suggested that personalised risk
21 messages can increase engagement in stop smoking services and short-term abstinence; however,
22 no evidence currently exists about how this translates to sustained quit rates.[36,37]

23 The current findings suggest that presenting lung age to the target group for lung cancer screening
24 may have unintended adverse consequences in discouraging smoking cessation, in contrast to
25 evidence from previous studies involving younger and more affluent groups. For example, Parkes et

1 al. reported increased likelihood of a quit attempt when lung age was provided to current smokers,
2 however participants in this study were younger (with an average age of 53).[38] It is possible that in
3 a population of older adults experiencing high levels of socioeconomic deprivation, lung age can be
4 difficult to interpret and demotivating when taking into consideration general low expectations of
5 health, life expectancy and well-being.[39]

6 Our findings reinforce the importance of emphasising the proximal short-term benefits of cessation
7 with the target population to increase response efficacy. Participants highlighted the importance of
8 providing verbal explanations delivered by trained practitioners to increase understanding of the
9 scan images and reinforce the immediate and concrete gains to be made from quitting smoking.
10 Shorter-term future orientation is not only important when providing information on personal lung
11 cancer risk and screening results, but in the delivery of behaviour change techniques to invoke quit
12 attempts and cessation. When taking into account the competing influences and wider social
13 determinants of health [40] that can act as barriers to achieving distal goals, short-term attainable
14 goals with high quality goal setting, are viewed to be more achievable and can thus lead to instant
15 results.[41,42] This short-term orientation may strengthen an individual's perceptions of both their
16 self-efficacy for reducing risk and the response-efficacy of smoking cessation for their health;
17 perceptions that the EPPM proposes are instrumental to achieving behaviour change in personalised
18 risk interventions.

19 There were limitations to our study. We were unable to obtain further demographic details from the
20 relatively small sample of online survey participants. Due to difficulties associated with the
21 recruitment of current smokers to a focus group about a smoking cessation intervention, we
22 sampled both people who currently smoke and people who recently quit smoking; however, former
23 smokers included were those who had quit less than one year prior to data collection to ensure that
24 we garnered views from people who had recent experience of smoking cessation.

25 **CONCLUSION**

1 Smoking cessation interventions that incorporate patients' scan images to highlight the personalised
2 benefits of cessation, in combination with supportive conversations with a trained practitioner
3 designed to enhance self-efficacy and response-efficacy, could motivate and sustain quit attempts in
4 people who currently smoke participating in lung cancer screening. The personalised cessation and
5 relapse prevention intervention is being evaluated in the YESS study as part of YLST.

6 **LIST OF ABBREVIATIONS**

7 LDCT - low-dose computed tomography

8 YESS – Yorkshire Yorkshire Enhanced Stop Smoking

9 YLST- Yorkshire Lung Screening Trial

10 EPPM - Extended Parallel Processing Model

11 **DECLARATIONS**

12 **Ethical approval and consent to participate**

13 Ethical approval was provided by Cardiff University School of Medicine Research Ethics Committee
14 (ref 17/51). Written consent was obtained from all participants.

15 **Consent for publication**

16 Written consent to publish quotes from the qualitative research was obtained from all participants.

17 **Availability of data and materials**

18 Data sharing is available upon reasonable request. Please contact the corresponding author. The
19 intervention materials are included as additional files.

20 **Competing interests**

21 The authors declare no competing interests.

1 **Funding**

2 The intervention development work was funded by the Cardiff University T. Maelgwyn Davies
3 Bequest Fund for the purpose of informing the Yorkshire Enhanced Stop Smoking Study (YESS;
4 ISRCTN63825779), funded by Yorkshire Cancer Research. SLQ is supported by a Cancer Research UK
5 Postdoctoral Fellowship (C50664/A24460). PAJC is supported by the NIHR Manchester Biomedical
6 Research Centre (BRC-1215-20007). GM is supported by Health and Care Research Wales as part of
7 the Wales Cancer Research Centre (517190). HSQ is supported by Health and Care Research Wales
8 as part of the Primary and Emergency Care Research Centre (PRIME) (517195).

9 **Author contributions**

10 Materials for the online survey and focus groups were drafted by GM. RM, KB, MC and SQ provided
11 substantial input and expert advice to develop and refine draft materials that were shown in the
12 online survey and focus groups. All authors contributed to the development and refinement of
13 intervention materials. GM and PS conducted the focus groups, and PS conducted the focus group
14 data analysis. HQS drafted the manuscript and all authors contributed to the review and editing of
15 the manuscript. All authors read and approved the final manuscript.

16 **Acknowledgements**

17 The authors gratefully acknowledge all participants who took part in focus groups and completed
18 the online survey. We would like to thank the Nottingham Tobacco and Nicotine Discussion Group
19 for their contribution to the project. Thanks to the YESS trial management group (Alexandra Ashurst,
20 David Baldwin, Kate Brain, John Britton, Matthew Callister, Phillip Crosbie, Nicola Hawkes, Sarah
21 Lewis, Monica Londahl, Grace McCutchan, Rachael Murray, Richard Neal, Steve Parrott, Samantha
22 Quaife, Harriet Quinn-Scoggins, Suzanne Rogerson, Pamela Smith, Rebecca Thorley, Qi Wu) for their
23 continued support with the project.

24

1

2

3


4 REFERENCES

- 5 1. Public Health England. Healthier Lives, Premature Mortality. [Available from:
6 <http://healthierlives.phe.org.uk/topic/mortality>] Accessed July 2022
- 7 2. NHS Choices. Lung cancer-Causes 2015 [Available from:
8 <http://www.nhs.uk/Conditions/Cancer-of-the-lung/Pages/Causes.aspx>] Accessed July 2022
- 9 3. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on
10 male British doctors. *BMJ*. 2004;328(7455):1519
- 11 4. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in
12 former smokers. *J Natl Cancer Inst*. 1993;85(6):457-64
- 13 5. The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-
14 Dose Computer Tomographic Screening. *N Engl J Med*. 2011;4 365(5):395-409
- 15 6. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with
16 Volume CT Screening in a Randomized Trial. *N Engl J Med*. 2020; 382:503-513
- 17 7. Taylor KL, Sanderson Cox L, Zincke N, et al. Lung cancer screening as a teachable moment for
18 smoking cessation. *Lung Cancer*. 2007;56:125-134
- 19 8. Tanner NT, Kanodra NM, Gebregziabher M, et al. The Association between Smoking
20 Abstinence and Mortality in the National Lung Screening Trial. *Am J Respir Crit Care Med*.
21 2016;193(5):534-41
- 22 9. Tammemägi MC, Berg CD, Riley TL, et al. Impact of lung cancer screening results on smoking
23 cessation. *Journal of the National Cancer Institute*. 2014;106(6):dju084
- 24 10. Park ER, Gareen IF, Japuntich S, et al. Primary Care Provider-Delivered Smoking Cessation
25 Interventions and Smoking Cessation Among Participants in the National Lung Screening
26 Trial. *JAMA Intern Med*. 2015;175(9):1509-16
- 27 11. Villanti AC, Jiang Y, Abrams DB, et al. A cost-utility analysis of lung cancer screening and the
28 additional benefits of incorporating smoking cessation interventions. *PLoS One*.
29 2013;8(8):e71379
- 30 12. Goffin JR, Flanagan WM, Miller AB, et al. Cost-effectiveness of Lung Cancer Screening in
31 Canada. *JAMA Oncol*. 2015;1(6):807-13
- 32 13. Cao P, Jeon J, Levy DT, et al. Potential Impact of Cessation Interventions at the Point of Lung
33 Cancer Screening on Lung Cancer and Overall Mortality in the United States. *Journal of*
34 *Thoracic Oncology*. 2020;15:7:P1160-1169
- 35 14. Brain K, Carter B, Lifford KJ, et al. Impact of low-dose CT screening on smoking cessation
36 among high-risk participants in the UK Lung Screening Trial. *Thorax*. 2017;72:912-918
- 37 15. Clark MM, Sanderson Cox L, Jett JR, et al. Effectiveness of smoking cessation self-help
38 materials in lung cancer screening population. *Lung Cancer*. 2004;44(1):13-21
- 39 16. Siahpush M, McNeill A, Borland R, et al. (2006). Socioeconomic variations in nicotine
40 dependence, self-efficacy, and intention to quit across four countries: findings from the
41 International Tobacco Control (ITC) Four Country Survey. *Tobacco Control*. 2006;15Suppl3,
42 iii71–iii75


17. Hiscock R, Judge K, Bauld, L. Social inequalities in quitting smoking: What factors mediate the relationship between socioeconomic position and smoking cessation? *Journal of Public Health*. 2011; 33, 39–47
18. Office for National Statistics. Chapter 1 - Smoking (General Lifestyle Survey Overview - a report on the 2011 General Lifestyle Survey) 2013 [Available from: http://www.ons.gov.uk/ons/dcp171776_302558.pdf] Accessed July 2022
19. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. *Lancet Oncology*. 2017;18(12):754-766
20. Pineiro B, Simmons VN, Palmer AM, et al. Smoking cessation interventions within the context of Low-Dose Computed Tomography lung cancer screening: a systematic review. *Lung Cancer*. 2016;98:91-98
21. Smith P, Poole R, Mann M, et al. Systematic review of behavioural smoking cessation interventions for older smokers from deprived backgrounds. *BMJ Open*. 2019;9:e032727. doi:10.1136/bmjopen-2019-032727.
22. Skivington K, Matthews L, Simpson S A, Craig P, Baird J, Blazeby J M et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. *BMJ*. 2021;374:n2061 doi:10.1136/bmj.n2061
23. French DP, Cameron E, Benton JS, et al. Can Communicating Personalised Disease Risk Promote Healthy Behaviour Change? A Systematic Review of Systematic Reviews. *Annals of Behavioral Medicine*. 2017;51:718-729
24. Hollands GJ, Hankins M, Marteau TM. Visual feedback of individuals' medical imaging results for changing health behaviour. *Cochrane Database of Systematic Reviews*. 2010;20(1): CD007434
25. Bize R, Burnand B, Mueller Y, et al. Biomedical risk assessment as an aid for smoking cessation. *Cochrane Database of Systematic Reviews*. 2005:Issue 4.
26. Witte, K. Putting the fear back into fear appeals: The extended parallel process model. *Communication Monographs*. 1992;59:329-349
27. Murray RL, Brain K, Britton J, et al. The Yorkshire Enhanced Stop Smoking study (YESS): a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme. *BMJ Open*. 2020;10:e037086, doi:10.1136/bmjopen-2020-037086
28. Crosbie PAJ, Gabe R, Simmonds I, et al. The Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low dose computed tomography screening for lung cancer versus usual care in a targeted population at risk. *BMJ Open*. 2020;10:e037075. doi: 10.1136/bmjopen-2020-037075
29. Batalden M, Batalden P, Margolis P, et al. Co-production of healthcare service. *BMJQualSaf*. 2016;25(7):511.
30. Robins Sadler G, Lee H-C, Seung-Hwan Lim H, et al. Recruitment of hard-to-reach population subgroups via adaptations of the snowball sampling strategy. *Nursing and Health Sciences*. 2010;12:369-374.
31. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in Psychology*. 2006;3(2):77-101
32. Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research *BMJ*. 2017;358:j3453 doi:10.1136/bmj.j3453
33. Bovet P, Perret F, Cornuzm J, et al. Improved smoking cessation in smokers given ultrasound photographs of their own atherosclerotic plaques. *Preventive Medicine*. 2002;34(2):215-220
34. Clair C, Mueller Y, Livingstone-Banks J, et al. Biomedical risk assessment as an aid for smoking cessation. *Cohrane Database of Systematic Reviews*. 2019;26;3(3):CD004705
35. Sherratt FC, Marcus MW, Robinson J, et al. Electronic cigarette use and risk perception in a Stop Smoking Service in England. *Addiction Research and Theory*. 2016;23(4):336-342

- 1 36. Gilbert H, Sutton S, Morris R, et al. Effectiveness of personalised risk information and taster
2 sessions to increase the uptake of smoking cessation (Start2quit): a randomised controlled
3 trial. *The Lancet*. 2017;389(10071):823-833
- 4 37. Zeliadt SB, Greene PA, Krebs P, et al. A Proactive Telephone-Delivered Risk Communication
5 Intervention for Smokers Participating in Lung Cancer Screening: A Pilot Feasibility Trial.
6 *Journal of Smoking Cessation*. 2017;13(3):137-144
- 7 38. Parkes G, Greenhalgh T, Griffin M, et al. Effect on smoking quit rate of telling patients their
8 lung age: the Step2quit randomised controlled trail. *BMJ*. 2008;15: 336(7644):598-600
- 9 39. Jordan H, Hidajat M, Payne N, et al.. What are older smokers' attitudes to quitting and how
10 are they managed in primary care? An analysis of the cross-sectional English Smoking Toolkit
11 Study. *BMJ Open*. 2017;7(11):e018150.
- 12 40. Dahlgren G, Whitehead M. "Policies and strategies to promote social equity in health.
13 Background document to WHO - Strategy paper for Europe," Arbetsrapport. 2007:14,
14 Institute for Futures Studies.
- 15 41. Bandura A. Health Promotion by Social Cognitive Means. *Health Education & Behaviour*.
16 2004;31(2):143-164
- 17 42. Lorencatto F, West R, Bruguera C, et al. Assessing the Quality of Goal Setting in Behavioural
18 Support for Smoking Cessation and its Association with Outcomes. *Annals of Behavioral*
19 *Medicine*. 2016;50:310-318


- A.** Based on information we have collected about you we have worked out how stopping smoking would affect your specific risk of developing lung cancer in the future. If 50 people like you continue to smoke, 4 people will develop lung cancer in 5 years' time. If 50 people like you stopped smoking today, 3 people will develop lung cancer in 5 years' time. That means out of 50 people like you, 1 fewer person will develop lung cancer in 5 years' time if they stop smoking.



- D.** The picture on the left is your lung. The picture on the right is a lung from a non-smoker. You can see that some parts of your lung are darker compared to the non-smoker's lung. These darker parts are where the lung has been damaged because of smoking.



Areas of damaged lung from smoking




A healthy lung that has not been damaged by smoking


- B.** Based on information we have collected about you we have worked out how stopping smoking would affect your specific risk of developing lung cancer in the future. If 50 people like you continue to smoke, 4 people will develop lung cancer in 5 years' time. If 50 people like you stopped smoking today, 3 people will develop lung cancer in 5 years' time. That means out of 50 people like you, 1 fewer person will develop lung cancer in 5 years' time if they stop smoking.



C.



- E.** The picture on the left is your heart. The white parts on your heart mean that the arteries going to your heart are narrower than those of a non-smoker's heart. This is because smoking can cause narrowing of the artery going to the heart. The picture on the right shows the difference between a normal and narrow artery.



- F.** We can work out how old someone's lungs are based on the information about them. For example, even though someone is actually 55 years old, because of various things like how much they smoke, their lung age might be 72 years old.